公开(公告)号：US20140128339A1

公开(公告)日：2014-05-08

申请号：US14054424

申请日：2013-10-15

申请人： Vinay Girijavallabhan ,  Stephane Bogen ,  Quang T. Truong ,  Ping Chen ,  Angela Kerekes ,  Frank Bennett ,  Sara Esposite ,  Qingmei Hong ,  Ian Davies

发明人： Vinay Girijavallabhan ,  Stephane Bogen ,  Quang T. Truong ,  Ping Chen ,  Angela Kerekes ,  Frank Bennett ,  Sara Esposite ,  Qingmei Hong ,  Ian Davies

IPC分类号： C07H19/06 ,  A61K45/06 ,  A61K31/7072 ,  C07H19/10 ,  A61K31/7068

CPC分类号： C07H19/06 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/067 ,  C07H19/073 ,  C07H19/10

摘要： The present invention relates to 2′-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relates to compositions comprising at least one 2′-Methyl Substituted Nucleoside Derivative, and methods of using the 2′-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

摘要翻译： 本发明涉及式（I）的2'-甲基取代的核苷衍生物及其药学上可接受的盐，其中R，R 1，R 2和R 3如本文所定义。 本发明还涉及包含至少一种2'-甲基取代的核苷衍生物的组合物，以及使用2'-甲基取代的核苷衍生物治疗或预防患者HCV感染的方法。

公开(公告)号：US10442819B2

公开(公告)日：2019-10-15

申请号：US15532549

申请日：2015-12-01

申请人： Christian Fischer ,  Stephane L. Bogen ,  Matthew L. Childers ,  Francesc Xavier Fradera Llinas ,  J. Michael Ellis ,  Sara Esposite ,  Qingmei Hong ,  Chunhui Huang ,  Alexander J. Kim ,  John W. Lampe ,  Michelle R. Machacek ,  Daniel R. McMasters ,  Ryan D. Otte ,  Dann L. Parker, Jr. ,  Michael Reutershan ,  Nunzio Sciammetta ,  Pengcheng P. Shao ,  David L. Sloman ,  Feroze Ujjainwalla ,  Catherine White ,  Zhicai Wu ,  Yang Yu ,  Kake Zhao ,  Craig Gibeau ,  Tesfaye Biftu ,  Purakkattle Biju ,  Lei Chen ,  Joshua Close ,  Peter H. Fuller ,  Xianhai Huang ,  Min K. Park ,  Valdimir Simov ,  David J. Witter ,  Hongjun Zhang

发明人： Christian Fischer ,  Stephane L. Bogen ,  Matthew L. Childers ,  Francesc Xavier Fradera Llinas ,  J. Michael Ellis ,  Sara Esposite ,  Qingmei Hong ,  Chunhui Huang ,  Alexander J. Kim ,  John W. Lampe ,  Michelle R. Machacek ,  Daniel R. McMasters ,  Ryan D. Otte ,  Dann L. Parker, Jr. ,  Michael Reutershan ,  Nunzio Sciammetta ,  Pengcheng P. Shao ,  David L. Sloman ,  Feroze Ujjainwalla ,  Catherine White ,  Zhicai Wu ,  Yang Yu ,  Kake Zhao ,  Craig Gibeau ,  Tesfaye Biftu ,  Purakkattle Biju ,  Lei Chen ,  Joshua Close ,  Peter H. Fuller ,  Xianhai Huang ,  Min K. Park ,  Valdimir Simov ,  David J. Witter ,  Hongjun Zhang

IPC分类号： A61K31/351 ,  A61K31/4353 ,  A61K31/5355 ,  A61K31/551 ,  C07D471/04 ,  C07D471/14 ,  C07D498/08 ,  C07D471/08 ,  C07D498/04 ,  C07D498/10 ,  A01N43/00

摘要： The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.